CBD gel tested for Long-Term safety in fragile x kids and young adults

NCT ID NCT03802799

Ongoing Disease control Sponsor: Zynerba Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at the long-term safety of a CBD gel (ZYN002) applied to the skin for children, teens, and young adults with Fragile X syndrome. Participants from two earlier studies will use the gel twice daily for 52 weeks. The main goal is to check for side effects, with a secondary focus on whether symptoms improve.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

cannabidiol (CBD) gel applied to the skin

What this could lead to

If successful, this could show that daily CBD gel is safe and may help manage symptoms of Fragile X syndrome over the long term.

What could go wrong

This is an extension study, not a new treatment test. It focuses on safety, not proof of effectiveness. Results may not apply to everyone with Fragile X.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fragile X syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FRAGILE X SYNDROME

Contacts and locations

Show contact details

Locations

Amnova Clinical Research, LLC

Irvine, California, 92604, United States
Boston Children's Hospital

Boston, Massachusetts, 02115, United States
Central States Research

Tulsa, Oklahoma, 74136, United States
Children's Clinical Research Facility, Royal Hospital for Children and Young People

Edinburgh, Lothian, EH105HF, United Kingdom
Children's Hospital of Colorado

Denver, Colorado, 80045, United States
Children's Research Institute

Washington D.C., District of Columbia, 20010, United States
Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229, United States
Genetics Clinics Australia

Melbourne, Victoria, 3161, Australia
Greenwood Genetic Center

Greenville, South Carolina, 29605, United States
Han Phan

Atlanta, Georgia, 30329, United States
Kennedy Krieger Institute

Baltimore, Maryland, 21205, United States
Lady Cilento Children's Hospital - South Brisbane

Brisbane, Queensland, 4101, Australia
Manchester University NHS Foundation Trust

Manchester, M13 9WL, United Kingdom
Masonic Institute of Developing Brain

Minneapolis, Minnesota, 55414, United States
Penn State Milton S. Hershey Medical Center

Hershey, Pennsylvania, 17033, United States
Primary Children's Hospital

Salt Lake City, Utah, 84113, United States
Research Space

Leicester, Leicestershire, LE15WW, United Kingdom
Rush University Medical Center

Chicago, Illinois, 60612, United States
Science 37

Culver City, California, 90230, United States
Southwest Autism Research and Resource Center

Phoenix, Arizona, 85006, United States
The Fragile X Spectrum Disorder Clinic at Icahn School of Medicine at Mount Sinai, Division of Medical Genetics

New York, New York, 10029, United States
UC Davis Health System, MIND Institute

Sacramento, California, 95817, United States
University of Miami

Miami, Florida, 33136, United States
University of Mississipi Medical Center

Jackson, Mississippi, 39216, United States
Wellington Hospital

Wellington, 6021, New Zealand
Westmead Children's Hospital

Sydney, New South Wales, 2145, Australia